Chon et al. Author Manuscript Published OnlineFirst on DOI: 10.1158/1078-0432.CCR-18-1932 Potentiation of immunotherapy by oncolytic vaccinia virus Chon et al.
Introduction
Cancer immunotherapy with immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4 has demonstrated a potent and durable therapeutic efficacy and emerged as a new weapon in the war on cancer (1) (2) (3) (4) (5) (6) . However, the clinical efficacy of ICIs is confined to tumors with a T cell-inflamed tumor microenvironment (TME) (7, 8) . In poorly immunogenic tumors with few tumor-infiltrating lymphocytes (TILs), TME lacks the type I interferon signature and chemokines for T cell recruitment (9, 10) . Moreover, tumor vasculatures and stromal components may pose a barrier against intratumoral trafficking of T cells and their effector functions on tumor cells (11) (12) (13) . Therefore, additional therapeutic interventions are required for these non-T cell-inflamed tumors to appropriately remodel the TME to render these tumors more sensitive to ICI treatments (8, 14) .
Oncolytic viruses have been proposed as a novel class of anti-cancer therapy, and viruses with different backbones and transgenes are currently being evaluated in clinical trials (15) (16) (17) . Although the success of oncolytic viruses was initially predicted during the past decade based on their faster replication and enhanced oncolytic capability, they are now beginning to be recognized as an immunotherapeutic because the strongest and most durable responses after oncolytic virotherapy are coupled with successful induction of anti-tumor immunity with increased tumor-specific effector and memory T cells (16, (18) (19) (20) (21) . Nonetheless, because the therapeutic efficacy of oncolytic viruses was greatly hindered by immunosuppressive TME, releasing the brakes of the immune system is critical to maximize the immunotherapeutic efficacy of oncolytic viruses (22) (23) (24) (25) . Therefore, the combination of oncolytic viruses and ICIs is a rational and appealing strategy to overcome poorly immunogenic and immunosuppressive TME.
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JX-594 (pexastimogene devacirepvec, Pexa-vec) is an oncolytic vaccinia virus that is engineered to express an immune-activating transgene, GM-CSF, and that has the viral thymidine kinase gene disrupted (26, 27) . JX-594 showed impressive anti-cancer activity with low toxicity in preclinical and clinical studies. It has become one of the most feasible and promising oncolytic virus platforms in clinical development as one of the few oncolytic viruses in phase III clinical trials (27) (28) (29) (30) . In addition to its oncolytic and vascular disrupting activity, JX-594 is proposed to exert an in situ cancer vaccination effect because it can elicit the adaptive immune response against tumor antigens for selective tumor disruption and subsequent additional tumor antigen release (31, 32) . Although JX-594 is now in a phase III randomized clinical trial (NCT02562755) in advanced hepatocellular carcinoma (33) , few studies have characterized its immune modulatory functions in primary TME as well as distant lesions after JX-594 treatment (34) . Moreover, the optimal combination of JX-594 with immunotherapeutics such as ICIs has not yet been pursued and verified.
Here, we comprehensively dissected the dynamic remodeling of TME with a mouse variant of JX-594 (mJX-594, WR.TK -mGM-CSF, hereafter referred to as JX) and investigated its immunotherapeutic potential to provide a rational combinatorial strategy with ICIs in poorly immunogenic tumor models.
Author Manuscript Published OnlineFirst on December 11, 2018; DOI: 10.1158/1078-0432.CCR- 9 virus for 3 days, collected by centrifugation, then homogenized and centrifuged once more.
The virus-containing supernatant was layered onto a 36% sucrose cushion and centrifuged at 32,900 g, and the purified viral pellet was resuspended in 1 mM Tris, pH 9.0. To determine the viral titer, serially diluted virus in serum-free DMEM was applied onto a monolayer of U-2 OS cells for 2 h, and then 1.5% carboxymethylcellulose in DMEM supplemented with 2 % FBS was added. After 72 h, cells were stained with 0.1% crystal violet and plaques were counted. Laboratory. Starting at 9 weeks after birth, the volume of every palpable tumor nodule (>20 mm 3 ) was measured, and the total volume of all tumors combined was used to calculate the tumor burden per mouse. MMTV-PyMT mice were randomized according to their initial tumor burden, and were treated with 4 × 10 7 pfu of JX with or without anti-PD-1 (10 mg/kg) or anti-CTLA-4 (4 mg/kg) antibodies at the indicated time points. In particular, JX was injected intratumorally (1 × 10 7 pfu per tumor) in 4 randomly selected palpable tumors. After 4 weeks of treatment, mice were anesthetized and tissues were harvested for further analyses.
Tumor models and treatment regimens
Analyses for MMTV-PyMT was performed as previously described (37, 38) .
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software, La Jolla, CA) and PASW statistics 18 (SPSS). Values are represented as mean +/-standard error of the mean unless otherwise indicated. Statistical differences between means were tested using unpaired Student's t-tests. Survival curves were generated using the KaplanMeier method, and statistical differences between curves were analyzed using the log-rank test. The level of statistical significance was set at p < 0.05.
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Results

JX converts immunosuppressive non-inflamed tumors into inflamed tumors
To determine the immunomodulatory potential of the oncolytic virus JX, we extensively examined temporal changes in TME after single intratumoral injections of JX into the Renca tumors, which are resistant to immune checkpoint inhibitors (39) . The tumoral level of JX was already high at day 1, peaking at day 3, but was barely detectable at day 7 after the injection ( Fig. 1A and B) . Conversely, tumor vessel density was markedly reduced between days 1 and 3 but was recovered at day 7 and thereafter after the injection ( Fig. 1A and B peaking at day 7, and remaining at a high density at 2 weeks after injection ( Fig. 1A and B) , demonstrating distinct and long-lasting conversion of the non-inflamed tumor into a T cellinflamed tumor by JX. By comparison, CD11c + dendritic cells (DCs) transiently emerged at day 3 and then decreased in tumors. However, DCs accumulated in draining lymph nodes from day 5 where they interacted with CD8 + T cells ( Fig. 1A; Supplementary Fig. S1D ). In addition, the level of PD-L1 was low at day 0 and upregulated after JX treatment ( Fig. 1A and B). Intriguingly, the PD-L1 upregulation followed just after a massive influx of CD8 + TILs (Fig. 1C) , indicating activation of the PD-1/PD-L1 axis in an attempt to negatively regulate T cell-mediated immunity. Most PD-L1 + cells were cytokeratin + tumor cells, and some were CD11b + myeloid but were not T cells (Fig. 1D) Fig. S1A ).
To elucidate the cancer immune pathways modulated by JX, we further analyzed changes in expression of 750 immune-related genes in the Renca tumor following JX monotherapy, using a PanCancer Immune Profiling panel. Of note, expression levels of the genes (~100 genes) related to immune modulation, including activation of type I IFN signaling, DC maturation, and T cell activation, were significantly different between control-and JX-treated tumors ( Fig. 1E and F) . In particular, the genes related to inhibitory immune checkpoints (Pd-1, Pd-l1, Ctla-4, and Lag-3) and agonistic immune checkpoints (Icos, Gitr, and Cd27), Th1 and Th2 responses, and M1 macrophage polarization (Nos2 and Cd86) were upregulated in JX-treated tumors compared with control-treated tumors (Fig. 1G) . These results indicate that JX elicits long-term immune activation through dynamic changes in the TME to remodel non-inflamed tumors into T cell-inflamed tumors that can respond to ICIs.
JX augments intratumoral infiltration of CD8 + T cells and induces myeloid cell repolarization
JX-induced delay of tumor growth was dose-dependent ( Supplementary Fig. S2A ). In parallel, JX-induced increases in CD8 + T cell infiltration in both peritumoral and intratumoral regions were also dose-dependent (Supplementary Fig. S2B ). Indeed, flow cytometric subset analysis of the lymphoid cell compartment revealed that the JX-induced increase in absolute numbers of intratumoral CD8 + and CD4 + T cells was dose-dependent ( Supplementary Fig. S2C and S2D) . Although the number of CD4 Fig. S2I ). These findings demonstrate that repeated JX administration enhances anti-cancer immunity, leading to increased infiltration of activated T cells and repolarization of myeloid cells.
Intratumoral injection of JX leads to systemic and cancer-specific immune responses
To determine whether local injection of JX could induce a systemic immune response for 
Anti-cancer immunity plays a critical role in the overall therapeutic efficacy of JX
To determine which components of the immune system are responsible for the therapeutic efficacy of JX, we examined its effect on tumors in mice treated with neutralizing antibodies against CD8, CD4, or GM-CSF (Supplementary Fig. S4A ). Of special note, depletion of 
CD8
+ T cell (Supplementary Fig. S4D ), indicating that CD4 + T cells are involved in activation and recruitment of CD8 + T cells in TME. However, depletion of CD8 + T cells did not significantly alter infiltration of CD4 + T cells (Supplementary Fig. S4D ), indicating that CD8 + T cells did not affect CD4 + T cells in TME. These findings indicate that intratumoral JX treatment induces priming of CD8 + and CD4 + T cells, which may interact with each other to mediate anti-cancer immunity.
Previous virotherapy based on herpes and vaccinia viruses used GM-CSF as an immuneactivating transgene, which recruits and activates antigen-presenting cells that subsequently trigger T cell response (40) . However, the use of GM-CSF is still controversial because of its potential immunosuppressive roles in tumor progression, such as inducing proliferation of myeloid-derived suppressor cells (18) . Therefore, we explored whether GM-CSF is required for the therapeutic effect of JX. Interestingly, depletion of GM-CSF negated the anti-tumor effect of JX and reduced both CD8 + and CD4 + T cell levels, suggesting that GM-CSF is critical for the immunotherapeutic efficacy of JX ( Supplementary Fig. S4C and S4D) . Thus, both CD8 + and CD4 + T cells are indispensable mediators of the anti-cancer effect of JX, and GM-CSF is an essential regulator of T cell activation for the JX treatment.
Combination of JX with immune checkpoint blockade elicits an enhanced anti-cancer effect with augmented infiltration of T lymphocytes into the tumor
As shown earlier, while JX inflames the TME by enhancing the recruitment of CD8 + T cells, it concomitantly increases the expression of PD-L1, which hinders the anti-cancer effects of cytotoxic T cells. On the other hand, ICI monotherapy is ineffective in non-inflamed, T cellinsufficient tumors (8) . Therefore, we sought to combine the two modalities to compensate for their respective weaknesses.
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The combination of anti-PD-1 antibody (αPD-1) and JX reduced tumor growth by 70%, while αPD-1 and JX monotherapy delayed tumor growth by 23% and 44%, respectively (Fig.   3A) . In support of these findings, CD8
+ T cells were more highly infiltrated in both peritumoral (2.5-fold) and intratumoral (2.4-fold) regions of the tumors treated with combination therapy than those treated with JX ( Fig. 3B and C) . Furthermore, CD31 + tumor blood vessels were decreased by combination therapy compared to control (peritumoral and intratumoral regions, 1.8-fold and 2.6-fold, respectively; Fig. 3B and C; Supplementary Fig.   S5A ), and tumor apoptosis was most severely induced in tumors treated with combination therapy compared with all other groups ( Fig. 3B and C; Supplementary Fig. S5B ).
Similarly to our initial findings (Fig. 1A-C) , although the PD-L1 expression was minimal in control tumors, it was upregulated by 2.1~3.7 fold in both peritumoral and intratumoral regions of JX-treated tumors ( Fig. 3B and C; Supplementary Fig. S5B ), implying that PD-L1 involves an adaptive negative feedback mechanism that dampens anti-cancer immunity after oncolytic virotherapy.
Next, to determine whether combination therapy is effective against distant untreated tumors as well as injected tumors, we treated mice carrying bilateral Renca tumors with JX and/or αPD-1 (Supplementary Fig. S5C ). The combination therapy more potently suppressed the growth of distant untreated tumors compared to JX or ɑPD-1 monotherapy.
Therefore, our findings indicate that combining JX and ICI not only potentiates the systemic immunotherapeutic effect of JX virotherapy but also overcomes resistance against ICI monotherapy through enhanced anti-cancer immunity by increasing CD8 + T cell infiltration (Fig. 3D) .
Cancer Research. We further validated our hypothesis by testing the efficacy of combination treatment with anti-CTLA-4 antibody (αCTLA-4) and JX. Although tumor growth was modestly inhibited by either JX (42.0%) or αCTLA-4 (20.0%) monotherapy, combination therapy displayed the most potent inhibitory effect (57.6%) (Supplementary Fig. S6A ). In addition, CD8 + T cells were more highly accumulated in both peritumoral (1.9-fold increase) and intratumoral (1.9-fold increase) regions of tumors treated with combination therapy compared with JX ( Supplementary Fig. S6B and S6C) . CD31 + tumor blood vessels were also disrupted in both peritumoral and intratumoral regions of combination therapy-treated tumors compared with control (2.1-fold and 3.8-fold reductions, respectively; Supplementary Fig. S6B and S6C ).
Furthermore, flow cytometry revealed that intratumoral infiltration of CD8 + and CD4 + T cells was also increased by JX and αCTLA-4 combination therapy (Supplementary Fig. S6D ).
Taken together, these results indicate that combination therapy using JX and ICIs can overcome the resistance against immunotherapy in immunosuppressive TMEs, resulting in enhanced anti-cancer effects.
The efficacy of combination immunotherapy with intratumoral JX and ICIs is not largely affected by treatment schedule
Because ICIs can negatively affect viral replication and lead to premature clearance of the oncolytic virus, previous studies explored the optimal schedules of treatment using combinations of systemic oncolytic virotherapy and ICIs and reported that some combination schedules could antagonize the therapeutic efficacy (22, 41) . However, the dependency of local oncolytic virotherapy on the treatment schedule of ICIs has not been reported. To establish the optimal combination schedule for intratumoral JX and ICIs, we compared the following: (1) simultaneous administration of JX and ICI (schedule I); (2) initiation of ICI 3
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days after administration of JX (schedule II); and (3) administration of JX 3 days after initiation of ICI (schedule III) (Fig. 4A) . All combination schedules delayed tumor growth by ~40% (Fig. 4B) . Likewise, levels of tumor-infiltrating CD8 + and CD4 + T cells were increased by >8.0-fold and >4.0-fold, respectively, and the expression of ICOS and GzB in CD8 + T cells was remarkably increased compared to control regardless of treatment schedule ( Fig. 
4C and D).
Similar to combination therapy with JX and αPD-1, the combination of JX and αCTLA-4 inhibited tumor growth by ~40% regardless of the treatment schedule (Supplementary Fig.   S7A ). Furthermore, intratumoral infiltration of CD8 + and CD4 + T lymphocytes (>7-fold and >7-fold increases, respectively) and GzB and ICOS expression in CD8 + T cells were greater regardless of treatment schedule ( Supplementary Fig. S7B and S7C) . ( Fig. 5A) . Of note, a few mice (~40%) of this triple combination group exhibited complete tumor regression, which was not observed in any other groups (Fig. 5B) . Furthermore, mice with complete tumor regression were tumor-free for more than 14 weeks after treatment cessation. They also were fully protected against re-challenge with Renca tumor cells but were not immune to CT26 tumor cells, suggesting the establishment of an effective, longterm, and tumor-specific immune memory (Fig. 5C) .
To establish that the potent anti-cancer effects induced by triple combination therapy could translate into a long-term survival benefit, we performed survival analyses of tumor-bearing mice (Fig. 5D ). Mice treated with triple-combination immunotherapy showed a remarkably better overall survival compared to results with monotherapy or dual-combination therapy. Intriguingly, the difference between dual and triple combination therapy was not remarkable early in the treatment period, but it increased over time and was maintained for a long time.
Therefore, triple combination therapy is needed to induce durable immunotherapeutic effects and longer survival. In conclusion, these findings demonstrate that triple combination immunotherapy has the potential to induce complete tumor regression and long-term survival.
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Furthermore, triple-combination therapy led to a 48.1% reduction in average tumor nodule size and better overall survival compared to other treatments ( Fig. 6E and F) . Histological analyses revealed less invasive carcinoma with well-preserved tumor margins in the triple combination group, indicating that triple combination effectively delays tumor progression and invasion (Fig. 6G) . Moreover, intratumoral recruitment of CD8 + T cells was further increased by 2.0-fold in tumors treated with triple combination therapy compared with those treated with JX monotherapy (Fig. 6H) . However, tumor vascular density was similar among the treatment groups (Fig. 6H) , indicating that the vascular disrupting effect is not longlasting after repeated JX injections. Finally, the number of hematogenous lung metastases was significantly reduced in the triple combination group (Fig. 6I) , indicating an effective Previous studies have reported that although the combination of an oncolytic virus and ICIs elicits an impressive immune response, the therapeutic efficacy can be affected by administration route and treatment schedule (22, 41, 48) . In particular, when both the oncolytic virus and ICIs are systemically administered simultaneously, the combination could be antagonistic because of the ICI-induced anti-viral immunity that can facilitate premature viral clearance, indicating the importance of an adequate time gap in between treatments for the oncolytic virus to induce a successful anti-cancer immunity (41, 49) . In the present study, local injection of JX consistently induced anti-cancer immunity without being significantly affected by administration sequences. We presume that this result is attributable to the intratumoral injection having provided the oncolytic virus a sufficient time lag to inflame the TME before being detected and eliminated by systemic antiviral immunity. Indeed, in tumors treated with intratumoral JX, concurrent ɑPD-1 treatment had almost no effect on the tumoral level of JX, in contrast to the markedly decreased level of JX in tumors treated with intravenous JX. Therefore, intratumoral virotherapy may be more suitable for designing clinical trials with the ICI and oncolytic virus combination compared with systemic virotherapy in terms of administration schedule.
In this study, we were not able to exclude the possibility that the immunogenicity of mouse model was affected by a tumor implantation-induced inflammatory reaction (50) . While we performed every treatment 10 or 12 days after tumor implantation to minimize inflammatory reaction, the level of the response to treatment that we observed in this study may not fully reflect the immune reaction in human cancer. Therefore, the findings of this preclinical study should be confirmed in clinical trials. 
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colon cancer (ClinicalTrials.gov: NCT03071094, NCT02977156, NCT03294083, and NCT03206073). Thus, we will be able to verify the findings of this study in a clinical setting in the near future.
In conclusion, these results indicate that intratumoral injection of JX induces a profound remodeling of TME from cold to hot state and elicits robust anti-cancer immunity in combination with ICIs, overcoming immunotherapy resistance.
